Plenvu is a colon-cleansing drug owned by Salix. Its active ingredients include Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; and Sodium Sulfate. It was first authorized for market use on May 4, 2018. So far, the company holds 10 drug patents for Plenvu.
The drug's patent protection extends up to September 10, 2033, which is when generic versions of Plenvu could potentially be released on the market.
The drug can be used for cleansing of the colon in preparation for colonoscopy in adults. Its effectiveness is attributed to its active ingredients such as Polyethylene Glycol 3350, which works as an osmotic laxative pulling water into the colon to induce bowel movement; and other electrolyte constituents that help balance the body's fluid levels.
Plenvu holds a total of 10 patents pertaining to its formulation and use. The last patent is set to expire on September 10, 2033. For more information about Plenvu generic release and patent details, refer to the following patent summary. Below are the details of the patent: